Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Targeted screening for Coeliac Disease among irritable bowel syndrome patients: analysis of cost-effectiveness and value of information.

Mohseninejad L, Feenstra T, van der Horst HE, Woutersen-Koch H, Buskens E.

Eur J Health Econ. 2013 Dec;14(6):947-57. doi: 10.1007/s10198-012-0441-4. Epub 2012 Nov 18.

PMID:
23179163
2.

Testing for celiac sprue in irritable bowel syndrome with predominant diarrhea: a cost-effectiveness analysis.

Spiegel BM, DeRosa VP, Gralnek IM, Wang V, Dulai GS.

Gastroenterology. 2004 Jun;126(7):1721-32.

PMID:
15188167
3.
4.

A preliminary model-based assessment of the cost-utility of a screening programme for early age-related macular degeneration.

Karnon J, Czoski-Murray C, Smith K, Brand C, Chakravarthy U, Davis S, Bansback N, Beverley C, Bird A, Harding S, Chisholm I, Yang YC.

Health Technol Assess. 2008 Jun;12(27):iii-iv, ix-124.

5.
6.

Economic evaluation of linaclotide for the treatment of adult patients with irritable bowel syndrome with constipation in the United States.

Huang H, Taylor DC, Carson RT, Sarocco P, Friedman M, Munsell M, Blum SI, Menzin J.

J Med Econ. 2015 Apr;18(4):283-94. doi: 10.3111/13696998.2014.979291.

PMID:
25333331
7.

Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs.

Paltiel AD, Walensky RP, Schackman BR, Seage GR 3rd, Mercincavage LM, Weinstein MC, Freedberg KA.

Ann Intern Med. 2006 Dec 5;145(11):797-806.

PMID:
17146064
8.

Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.

Garside R, Pitt M, Somerville M, Stein K, Price A, Gilbert N.

Health Technol Assess. 2006 Mar;10(8):1-142, iii-iv. Review.

9.

Coeliac disease in irritable bowel syndrome (Rome III) in Southeast Iran.

Bakhshipour A, Nezam SK, Zakeri Z, Gharibi R, Bahari A, Kaykhaei MA.

Arab J Gastroenterol. 2012 Mar;13(1):24-7. doi: 10.1016/j.ajg.2012.03.003. Epub 2012 Apr 4.

PMID:
22560821
10.

Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting.

Manser R, Dalton A, Carter R, Byrnes G, Elwood M, Campbell DA.

Lung Cancer. 2005 May;48(2):171-85. Epub 2005 Jan 4.

PMID:
15829317
11.

Screening for Chlamydia trachomatis in women 15 to 29 years of age: a cost-effectiveness analysis.

Hu D, Hook EW 3rd, Goldie SJ.

Ann Intern Med. 2004 Oct 5;141(7):501-13. Erratum in: Ann Intern Med. 2004 Nov 2;141(9):744.

PMID:
15466767
12.

The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.

Fox M, Mealing S, Anderson R, Dean J, Stein K, Price A, Taylor RS.

Health Technol Assess. 2007 Nov;11(47):iii-iv, ix-248. Review.

13.

Screening for celiac disease in asymptomatic children with Down syndrome: cost-effectiveness of preventing lymphoma.

Swigonski NL, Kuhlenschmidt HL, Bull MJ, Corkins MR, Downs SM.

Pediatrics. 2006 Aug;118(2):594-602.

PMID:
16882812
14.

Value-of-information analysis to reduce decision uncertainty associated with the choice of thromboprophylaxis after total hip replacement in the Irish healthcare setting.

McCullagh L, Walsh C, Barry M.

Pharmacoeconomics. 2012 Oct 1;30(10):941-59. doi: 10.2165/11591510-000000000-00000.

PMID:
22667458
16.

Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy.

Sanders GD, Bayoumi AM, Sundaram V, Bilir SP, Neukermans CP, Rydzak CE, Douglass LR, Lazzeroni LC, Holodniy M, Owens DK.

N Engl J Med. 2005 Feb 10;352(6):570-85.

17.

The prevalence of celiac disease among patients with nonconstipated irritable bowel syndrome is similar to controls.

Cash BD, Rubenstein JH, Young PE, Gentry A, Nojkov B, Lee D, Andrews AH, Dobhan R, Chey WD.

Gastroenterology. 2011 Oct;141(4):1187-93. doi: 10.1053/j.gastro.2011.06.084. Epub 2011 Jul 14.

18.

Expanded screening for HIV in the United States--an analysis of cost-effectiveness.

Paltiel AD, Weinstein MC, Kimmel AD, Seage GR 3rd, Losina E, Zhang H, Freedberg KA, Walensky RP.

N Engl J Med. 2005 Feb 10;352(6):586-95.

19.

Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis.

Inadomi JM, Sampliner R, Lagergren J, Lieberman D, Fendrick AM, Vakil N.

Ann Intern Med. 2003 Feb 4;138(3):176-86.

PMID:
12558356
20.

Cost-effectiveness of alternative strategies for the initial medical management of non-ST elevation acute coronary syndrome: systematic review and decision-analytical modelling.

Robinson M, Palmer S, Sculpher M, Philips Z, Ginnelly L, Bowens A, Golder S, Alfakih K, Bakhai A, Packham C, Cooper N, Abrams K, Eastwood A, Pearman A, Flather M, Gray D, Hall A.

Health Technol Assess. 2005 Jul;9(27):iii-iv, ix-xi, 1-158. Review.

Supplemental Content

Support Center